2hats
Dust.
Codagenix's COVI-VAC single-dose, intranasal, live-attenuated vaccine demonstrates promising reactogenicity and immunogenicity results in a phase 1 dose escalation trial.
Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies
/PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced...
www.prnewswire.com